A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients

Trial Profile

A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics (Primary) ; Cyclophosphamide; Interferon alpha-2b
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors BriaCell Therapeutics Corp
  • Most Recent Events

    • 10 Sep 2018 Planned End Date changed from 1 Mar 2020 to 1 Mar 2019.
    • 10 Sep 2018 Planned primary completion date changed from 1 Feb 2020 to 1 Feb 2019.
    • 08 Aug 2018 According to a BriaCell Therapeutics media release, Cancer Center of Kansas (CCK) has been added as a new clinical trial site for this trial and Dr. Shaker R. Dakhil will be the principal investigator at this site.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top